- KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
- KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
- KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
- KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
- KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
- KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
- KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
More ▼
Key statistics
On Wednesday, Kalvista Pharmaceuticals Inc (KALV:NMQ) closed at 11.69, 62.14% above the 52 week low of 7.21 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.47 |
---|---|
High | 11.86 |
Low | 11.47 |
Bid | 9.99 |
Offer | 12.50 |
Previous close | 11.61 |
Average volume | 288.64k |
---|---|
Shares outstanding | 42.19m |
Free float | 41.71m |
P/E (TTM) | -- |
Market cap | 489.81m USD |
EPS (TTM) | -3.14 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼